Member Info for MaxHSpringer

OB! I personally think 50p+ by Crimbo

Yes OB! Go out tommorow at 7:45am and do not go home until 16:45

OB! That sofa has deep cushions!
If you go hunting in the sofa or probably in a jacket or two (that you haven't warn in a while), might might find some pennies to invest. But, please do so because you've done your own research and are happy to do so.
I am actually in the blue today on both accounts TGI10p+! Lol.
Anyway, I think there is news coming our way very soon!
I personally think that this is very undervalued!
This will gain traction imo and start the ascent! Obviously based on my research, the time following the company and the partial potential of this company! (Imagine the full potential)

I have spoken to several LTH's and it seems to be the consensus that these shares are well tucked away, because with the recent plan to bring in money through the farm in and investment of VAL subsidiaries in the form of SPV's will maximize profits while reducing the risk.
The idea is to have large pocket investors pay for development and trials in exchange for equity.
So, the overwhelming number of people I have spoken to are looking at north of 40p and longer term a much higher number.
With the right news you could add a 0 to the current share price.
I believe this as well.
I think that the catalyst will probably be news of funding for VAL401.

Another catalyst would be news that the Japanese pharma is wanting to find the further development of VAL301 in conjunction with their line of drugs to treat endometriosis.

Now, if you look it up on Google between 10-20% of women of child bearing age suffer from endometriosis.
This is regardless of ethnicity. So, imagine the potential size of such a market.

These are just some of the possible news we are expecting to get updates on this quarter. So IMO, VAl has the best risk reward with a hungry and eager new BOD who see the opportunity to really build something great here.
Now remember the previous BOD tried to steal the compounds and intelectual property. You don't build an elaborate scheme and legal structure to steal something that won't come to anything of value.
GLA I think we are on to a winner here!

I wouldn't be surprised if there is a funding announcement in the very near future!

She published the chart on linkedin

RB- that is a really good read and should an eye opener, for those who haven't done research on the new VAL

Correction- no point in mentioning the spv! We already knew about blackcat.

Yes
But not sure that this is what it is referring too! I think there is another iron heating up in the fire and really have a feeling that we wil be getting some very positive news on the Japanese pharma and 301!

Just an opinion but otherwise no Tel point to May 1st rns!

Yes
But 20% of a product that goes to market and someone else is paying for the development/trials, then that is a win.

Hello Borgie,

I have read all the rns's and am waiste deep in VAL and happy with my position.

There are a couple of things holding the share price here such as:

- People are out chasing rainbows because they think that there is only the trial headlines and think that it is coming at the end of September. We know and maybe the company can help highlight that there is other news that may arrive at anytime.

- People may be concerned that there will be dilution in the short term, so it would be helpful if the company could put people's minds at ease.

- The BOD are scientists and not really great at PR, so by answering some of my questions, I how that the penny will drop with people.

Remember the previous BOD did a or of damage to the company both financially and reputational, so imo the more the BOD can be out there and show that positive tangible things are happening.

So far there have been positive first steps in regards to policy and attitude towards shareholders. However, I think that if there is a negotiation going on, maybe the market should be told and I understand that they could reveal details, but ask yourself this- why mention SPV's without anything to differentiate it from just an idea?

IMO there is obviously a reason to mention SPV's because, I am of the view that an SPV is a solution to allow two parties to come together where assets and money is ring fences for a particular purpose .

There is no reason to publish a solution to a happy problem you do not yet have, or do we?

IMO and obviously putting 2+2=. I would Hazard a guess that the Japanese Pharma would want to take things to the next stage in regards to VAL301 as there is a Material Transfer Agreement, I point to the RNs on May 1st and the two paragraphs that look very interesting when you mention SPV's.

" 1 May 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, announces that it has signed an agreement with a global Japanese pharmaceutical company to evaluate Valirx's therapeutic, VAL301, for the purpose to contemplate a potential future license, for its use in the treatment of endometriosis."
And
"To both parties' mutual potential benefit therefore and under the terms of the MTA, ValiRx will supply the required quantities of compound, while the Japanese sponsor will be responsible for undertaking an agreed programme of work at its own expense."

So this is what is driving my hypothesis. Another thing that comes to mind is that they are in final negotiations for 401 funding and an SPV would be a good way to get the money and protect both parties. So, I think that there is something a foot with one of the two compounds and this could be a game changer. It it would be nice to hear that there is something happening straight from the BOD

Borgie,

I believe these questions to be reasonable. For instance: when you re running a business or an organisation (and anyone who runs one wil tell you), you should have a handle on your expenses, know your outgoings, break even point and basically how much you need to open your doors , everyday!
As such, it is my belief that a business that goes to the market knows this and as such should know, how much they need and how long it should last. Obviously, there are mitigating circumstances and a margin you leave yourself for unforseen expenses related to the day to day operations of the business.
Any manager who can not answer such a question, really should not be running a business.

So, on paper you would say that based on the recent rns's and outgoings- you would say that there is up to 30months or so if there are no incidentals, but realistically and having a safety margin, I would expect somewhere between 16- 24 months!

This is obviously for wages and keeping the business open. But I am very positive that if there is to be a deal it will be sometime in Q3 of this year to Q1 of 2021!
Obviously Covid lockdown has probably not done any favours. But this is where my thoughts are.

Another email from Dr. D

Hi ............

Thanks for the further questions – I’ll add these to the earlier question about the AGM, and answer in line with our communications protocol.



Best wishes,



Suzy

Hello,
I have the following questions for you and hope that you will be able to answer these in the next Q&A publication.

1. There is a lot of concern from shareholders" perspective in regards to further placings. So, based on recent cost cutting and placing, how long does the business anticipate that the money raised on last placing would last before a further injection of money would be required?.

2. In the rns dated 6th of July, Vaiirx introduced the shift in business model to atract investor/partners to further progress the development to clinicàl trials
Will the company receive income for the project management of the projects placed in the SPV's?

3) if the company will receive an income for the services provided to the SPV(s) and if so, would this be enough money for the business to oroceed- again without further placings?

4) Is Valirx currently in negotiations with an interested or potentially interested party that would require the formation of an SPV or other legal partnership?

5) as a follow up to the previous question. Is there an existing NDA that would not allow you to inform the market of the current stage of negotiations?

6) Based on previous updates from the former BOd, the market had been informed of the very good results/effectiveness of all four compounds (101, 201, 301 & 401), does the company still believe that the statements made from previous board and/or board members were accurate?

7) If Val201 is being looked at in order to treat Covid / SARS virus- is it correct to that this compound has anti-Viral properties and if so, could it have a desired affect on other viruses?

7.1) if the VAL201 has anti-Viral properties, does the company have a theoretical or hypothesis in regards to what other viruses it could be effective against?

8) with headline results due at some point in September. Does the business anticipate or is there a possibility of news on other compounds prior to September 2020?

I look forward to your posting and hope that the above questions are answered to the best of your ability.

Thank you

From RNS Monday 6th of July
"It is intended that new projects will be held in newly formed subsidiaries ("Special Purpose Vehicles" or "SPVs") with the Company seeking external funding from partners to progress development towards clinical trials. ValiRx will provide the SPVs with corporate and project management support, being reimbursed accordingly".
So, maybe a question to put on Q&A is "with the money raised from last placing and taking account of the current spend rate with cost cutting, how long does the company expect these funds to last before the need for additional funding or does the company have an active plan to partner with either an investor of pharma? If so, would this allow the company to be in a position where placings would not be required?

Freddie,
With the creation of SPV's for the development of ant one line with a partner(s). The company would be paid by the partner for the work it does.
This is what I understand from the RNs where she explains the new paradigm.
I'll post the date on next post
But my point is, that assuming the company gets partners for VAl 101, 201, 301 and 401 (or any of them)- the company wouldn't need to raise money.

Dear ...........

Thanks for your questions – I will include these in the next public answers sessions, which I will ensure is released prior to the AGM. By encouraging written questions to be submitted, and by answering them publicly, we hope to foster an environment of trust in our communications with shareholders, so I’m sure you understand why I cannot provide an immediate email answer to you personally and individually on this.



Please be assured that my attempts to improve shareholder communication are genuine and serious, and that without the pandemic situation, I would have been thoroughly looking forward to welcoming you all to the AGM, but while still endeavouring to make the information openly available to shareholder unable to travel to attend.



Best wishes,



Suzy

I've received an email reply from Dr. Dilly and as much as she couldn't answer my question today!

She did inform me that my query will be included in a Q& that will be posted prior to the AGM.

I've sent Dr. D an email:

Good morning Dr. Dilly,

I write to you as a shareholder in Valirx and would like to start by expressing my enthusiasm for the company, along with your involvement and team.

However, I do have two queries that I am sure that you could answer:

1) why can't the AGM be held via a platform such such as Skype, Microsoft Teans, Zoom or even a dial in conference call?

I believe that this would be more open and transparent and contribute to the healing of the company's reputationafter the previous BOD's conduct.

2) who are the two shareholders that will be at the meeting, this is very vague and again does not project the right optics from a shareholders perspective

Would you kindly re-evaluate and allow for the AGM to be done over a more open and transparent platform to allow for shareholders to witness this important meeting?

I look forward to your reply and wish you the best of luck in delivering the new strategy for Valirx

So, will let you all know what she says.

Why can't they do it as a dial in conference call?